{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMG6-JIKDA","lastupdate":"2020-12-02T00:00:00.000Z","update_date":"2020-12-02T00:00:00.000Z","lastModified":"May 10, 2021","active":1,"confidence_score":100,"confidence_score_reason":"","urlname":"targetgene","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$6FTl6xfvUX6OvSA8hDkWxVoMCsqyLZfnYMgoE8rEg4SfVTcz44d4nC","name":"TargetGene Biotechnologies","oneliner":"Genome Editing for Living Organisms","registrar":"514820604","website":"https://targetgenebio.com","careerspage":"https://targetgenebio.com/careers","founded_month":10,"founded_year":2012,"formernames":[],"sociallinks":{"twitter":"","youtube":"https://www.youtube.com/channel/UCfX49fh4T07F1Of1m1BLVnw","facebook":"","linkedin":"https://www.linkedin.com/company/3216766","instagram":""},"social":["https://www.linkedin.com/company/3216766","https://www.youtube.com/channel/UCfX49fh4T07F1Of1m1BLVnw"],"flattenedsociallinks":"https://www.linkedin.com/company/3216766|https://www.youtube.com/channel/UCfX49fh4T07F1Of1m1BLVnw","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":7,"patent":1,"raised":9200000,"stage":"B","public_stage":"Pre-Funding","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Target Gene"],"about":"TargetGene Biotechnologies is an innovative and agile biotechnology company in its development stage and poised for expansion. The companys R&D is centered around creating efficient and extremely specific DNA editing solutions in living organisms. \r\n\r\nThrough its patented and patent-pending TGEE (genome editing engine) platform, TargetGene has developed RNA-guided gene targeting. The company aims to implement the TGEE platform for human gene therapy with a focus on inherited diseases and cell-based immunotherapy.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97286758143","country":null,"address":{"israeli":[{"id":"584ef03e-e7d6-404c-8c66-32451193f38c","city":"Rehovot","type":null,"address":"Prof. Hillel ve-Khanan Oppenheimer St 10, Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"bbacff15-3404-4b1e-b4ce-e851ac5e4dd9","date":"Dec 11, 2019","link":"https://crisprmedicinenews.com/news/move-over-crispr-a-new-platform-tgee-could-soon-replace-everybodys-favorite-gene-editing-tool-i/","source":"crisprmedicinenews.com","visible":1,"analysis":{"tags":"gene therapy","company":"TargetGene Biotechnologies","layoffs":null,"summary":"TargetGene Biotechnologies, a genome editing company, has developed a unique molecular tool for editing DNA with higher specificity than CRISPR/Cas9. The companys system, called TGEE (TargetGene Genome-Editing Engine), uses two RNAs to guide the DNA-cutting enzymes to their target, making it much more specific and unlikely to cut unintended off-target sites in the genome. The system is currently about half as efficient as CRISPR, but the company believes it can improve efficiency to match or surpass CRISPR. TargetGene is targeting three therapeutic areas: cancer, hereditary diseases, and autoimmune diseases. The company is seeking investors to support its technology, and it aims to obtain FDA approval for its first application within a year and a half.","partners":null,"customers":null,"investors":"Adama","confidence":8,"key_topics":["gene-editing tool","specificity","efficiency","therapeutic targets","FDA approval"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Expand"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"8ZLeBgWXKUmesQfUfCi8PGuXxYDST2uynOOAngoHyh3HlukSM3IZ9C","news_summary":"Interview: Move over CRISPR: a new platform, TGEE, could soon replace everybody's favorite gene editing tool. Interview: Yoel Shiboleth, CEO TargetGene - CRISPR Medicine","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a7709366-7870-412a-9ab8-916dfd8a22d2","date":"Dec 26, 2018","link":"https://en.globes.co.il/en/article-targetgene-develops-more-precise-gene-editing-1001266555","source":"en.globes.co.il","visible":1,"analysis":{"tags":"gene editing","company":"TargetGene Biotechnologies","layoffs":null,"summary":"TargetGene Biotechnologies, a company specializing in gene editing, has developed an improved version of the CRISPR method. The companys founders, Dan Weinthal and Dr. Yoel Shiboleth, have experience in genetic engineering and have invented a protein that cuts DNA more precisely than CRISPR. TargetGene aims to replace CRISPR in human trials and believes its product is safer and more precise. The company is currently focused on medical applications of its technology, particularly in cancer treatment. TargetGene has received investments from Makhteshim Agan and Monsanto, and recently signed an agreement with a global drug manufacturer. The company is seeking additional financing to bring its product to market.","partners":null,"customers":null,"investors":["Makhteshim Agan","Monsanto"],"confidence":8,"key_topics":["CRISPR","gene editing","TargetGenes method","cancer treatment","investment"],"date_of_event":"2018-12-26","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment","Partners"],"acquisition_amount":null,"structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"2T4MLCa5h35mhWeh1x0phCLgloi4fcd9FZbuyjUPvXm4OQxmoBF5LI","news_summary":"TargetGene develops more precise gene editing","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"110cabbc-da22-402c-8db9-4a4ed70d66ab","date":"May 7, 2017","link":"https://www.wsj.com/articles/monsanto-bets-on-next-phase-of-high-tech-crops-but-its-not-alone-1494162000","source":"www.wsj.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"jJRWLu7qAFHAv1VT9nLjVJC5xLUHWoTJqu9ytK0CTCoZjcCwvSE1uD","news_summary":"Next Phase of High-Tech Crops: Editing Their Genes","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"386b8ab1-0ad4-4900-8a7d-6f6699edc567","date":"Jun 28, 2016","link":"https://www.genomeweb.com/business-news/monsanto-inks-gene-editing-tech-licensing-deals-targetgene-nomad-bioscience","source":"www.genomeweb.com","visible":1,"analysis":{"tags":"genome editing technologies","company":"Monsanto","layoffs":null,"summary":"Monsanto has announced two new licensing agreements for genome editing technologies with TargetGene Biotechnologies and Nomad Bioscience. Under the agreements, Monsanto has obtained exclusive licenses and equity positions in both firms. The agreements allow Monsanto to use TargetGenes genome editing engine (T-Gee) and Nomads technology for research projects and potentially for the development of commercial agricultural products. The partnerships aim to improve the efficiency of genome editing and the ability to deploy edited traits in commercial varieties. The financial terms of the agreements were not disclosed.","partners":["TargetGene Biotechnologies","Nomad Bioscience"],"customers":null,"investors":null,"confidence":8,"key_topics":["Licensing agreements","Genome editing technologies","TargetGene Biotechnologies","Nomad Bioscience","RNA-directed gene targeting"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"TP7B4BckAbMSB9uOH7fGDjQkkNrg8QmrE7EVEPv5WpBLdlKMRw0ZNF","news_summary":"Monsanto Inks Gene Editing Tech Licensing Deals With TargetGene, Nomad Bioscience","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":4,"techcommunityinvolvement":null,"mediagallery":[{"id":"8ba12cfc-34a5-4eac-8257-43bdbd4499cb","timestamp":"2020-03-17 09:51:50.000000","resources_type":2,"resources_title":"","resources_file_name":"vLAzu6UsouM","alt":"","imageurl":"https://img.youtube.com/vi/vLAzu6UsouM/0.jpg","url":"http://youtu.be/vLAzu6UsouM"},{"id":"20ac3449-df65-48f6-ba1a-32c157fd1613","timestamp":"2020-03-17 09:51:40.000000","resources_type":2,"resources_title":"","resources_file_name":"RnB8sE1Pub4","alt":"","imageurl":"https://img.youtube.com/vi/RnB8sE1Pub4/0.jpg","url":"http://youtu.be/RnB8sE1Pub4"}],"tags":["laboratories","medical-technologies","biotechnology","genomics","genetic-engineering","academia","genetics","patent-pending"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"technologysuccessstory":null,"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["T-Gee"],"geomarkets":["Global"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":2,"lastfunding":"$6.7M","totalrounds":2,"fundingstage":"B","totalfunding":"$9.2M","publicinvestors":0,"lastpublicfunding":null,"totalpublicrounds":0,"totalpublicfunding":0},"team":[{"name":"Yoel Shiboleth","email":"yoel@targetgenebio.com","phone":"0505959884","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLGXuIYIDA","bounced":true,"claimed":1,"founder":1,"urlname":"yoel-shiboleth","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAwYKNkQoM","position":"Co-founder & CEO","last_name":"Shiboleth","claimtoken":"e717fcc5cff4088d0f705741263ce25f8451157d198aa8b543aa0c4b77ab0be8","first_name":"Yoel","picturekey":"$W3ZCPlYAxY7EFDLSPZ0tejUp2lnhMpSluMsWcRJUQtWKyfaan8BGco","claimeddate":"2015-08-04","linkedinurl":"https://www.linkedin.com/in/yoelshiboleth","unsubscribed":false,"is_activeuser":0,"additionalemail":"shibolethy@gmail.com","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$W3ZCPlYAxY7EFDLSPZ0tejUp2lnhMpSluMsWcRJUQtWKyfaan8BGco","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Dan Weinthal","email":"weinthal@gmail.com","phone":"0547896155","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgOHs6KoIDA","bounced":false,"claimed":1,"founder":1,"urlname":"dan-weinthal","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAsaeD4wgM","position":"Co-founder & COO","last_name":"Weinthal","claimtoken":"01089795286e92e885d74189100bc0dc22fb03ec79d0c8515ee2f60a07896b8e","first_name":"Dan","picturekey":"$NdL5Xs7lfstyeTfBSJKSitbMMFIooO0zm8B7zSw7meHuV5YRulq3xb","claimeddate":"2015-08-04","linkedinurl":"https://www.linkedin.com/pub/dan-weinthal/12/179/314","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$NdL5Xs7lfstyeTfBSJKSitbMMFIooO0zm8B7zSw7meHuV5YRulq3xb","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Digital Health and Medical Technologies","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverifydate":"2020-03-17T00:00:00.000Z","crunchbaseid":"targetgene-biotechnologies","lastupdator":"Orli Wollner","lastupdator_email":"orlushka@gmail.com","creator":"Alyssa Williams","creator_email":"williamsar95@gmail.com","createdate":"2015-08-04T00:00:00.000Z","biverification":"Natalia Golczar","sectorverification":"Sharon Shapira","affiliatedOrganizations":null,"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkwIf6CQw","date":"Jun 2016","amount":"$6.7M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0213a3f7-c4c3-4137-aeb6-52b49601a357","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Monsanto","type":"Multinational","amount":0,"hidden":false,"country":"United States","fullurl":"/mnc_page/monsanto","logokey":"$Hq4gSDqLLOb8aefqrsDjn4JhfROxsew10C8mAFyu5VJpeWxlmXbDTH","tagline":"Agriculture","urlname":"/mnc_page/monsanto","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwISo-4EKDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"22209615-6a21-48a3-ab3a-4598b9607d3d","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Hq4gSDqLLOb8aefqrsDjn4JhfROxsew10C8mAFyu5VJpeWxlmXbDTH","leadcaption":"","followupcaption":""}],"eventvisibility":"Internal","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Internal</text>\n</div>'","sectionname":"Private Equity Funding","amountnumber":6700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEntjoCAw","date":"Jan 2013","amount":"$2.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Internal","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Internal</text>\n</div>'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"10/2012","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"TargetGene Biotechnologies","logourl":"https://storage.googleapis.com/clean-finder-353810/$6FTl6xfvUX6OvSA8hDkWxVoMCsqyLZfnYMgoE8rEg4SfVTcz44d4nC","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$6FTl6xfvUX6OvSA8hDkWxVoMCsqyLZfnYMgoE8rEg4SfVTcz44d4nC","seoabout":"TargetGene Biotechnologies is an innovative and agile biotechnology company in its development stage and poised for expansion. The companys R&D is centered...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":2,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationDelimited":["IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA"],"classificationsViewModel":"|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Genes#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Biotechnology","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Biotechnology"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Genes","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Genes"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Genes","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4NvztpMKDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Biotechnology","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQo-oIDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Genes"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Biotechnology"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODkwIf6CQw","date":"Jun 2016","amount":"$6.7M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Undisclosed Investor(s)","type":"Investor","amount":0,"hidden":false,"country":"Europe","fullurl":"/investor_page/undisclosed-investor-s","logokey":null,"tagline":"","urlname":"/investor_page/undisclosed-investor-s","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCE3L3CCgw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0213a3f7-c4c3-4137-aeb6-52b49601a357","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/investors-icon.svg","leadcaption":"","followupcaption":""},{"name":"Monsanto","type":"Multinational","amount":0,"hidden":false,"country":"United States","fullurl":"/mnc_page/monsanto","logokey":"$Hq4gSDqLLOb8aefqrsDjn4JhfROxsew10C8mAFyu5VJpeWxlmXbDTH","tagline":"Agriculture","urlname":"/mnc_page/monsanto","isisraeli":null,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwISo-4EKDA","fundingtype":"Multinational","leadpartner":null,"investmentid":"22209615-6a21-48a3-ab3a-4598b9607d3d","fundingsubtype":"","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Hq4gSDqLLOb8aefqrsDjn4JhfROxsew10C8mAFyu5VJpeWxlmXbDTH","leadcaption":"","followupcaption":""}],"eventvisibility":"Internal","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"B Round","style":"","hiddenCompanyTooltip":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Internal</text>\n</div>'","sectionname":"Private Equity Funding","amountnumber":6700000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCEntjoCAw","date":"Jan 2013","amount":"$2.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Internal","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/internal-visibility.svg\"/>\n    <text>Internal</text>\n</div>'","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":2500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}